Investigator (I or II) in Pharmaceutical & Formulation Science

Basic Qualifications: Ph.D. in Chemistry, Pharmaceutical, Biomaterials, Biomedical Science or related field plus at least 2-5 years of experience (min 2 years for Investigator II and 5 years for Investigator I). Alternatively an MS in Chemistry, Pharmaceutical, Biomaterials, Biomedical Science or related field plus at least (minimum 7 years experience for Investigator II and 12 years for Investigator I).

Salary Range: $75k – 110k per year, bonus $75k – 110k per year, bonus eligible

Benefits Package: Inimmune offers a competitive benefits package which includes health, dental and vision insurance; 401k program with matching and incentive stock options (ISOs) for employees

Position Details:

An Investigator position in formulation science/nanoparticle based vaccine delivery is available immediately at Inimmune Corp, as part of an interactive multidisciplinary research team focused on the discovery and development of novel vaccine adjuvants and immunotherapeutics. This is an excellent opportunity to join a world-class multidisciplinary research & development team that is well funded and has strong connections in both academia and industry. Inimmune is a thriving new company founded in 2016 with 31 total full-time or part time employees. We are looking for highly motivated candidates with a strong working knowledge of vaccine/drug formulation, bioconjugation and drug delivery, nanoparticle technology, pharmaceutical science, organic and analytical chemistry with a solid understanding of biochemistry or biological systems. Candidates should have excellent communication, writing and leadership skills for this position.

This Investigator will work under the supervision of Dr. David Burkhart (COO) to complete the exciting R&D work on novel immunotherapeutics for cancer and allergy, opioid vaccine bioconjugate technologies and other early stage research projects. This Investigator will be expected to supervise multiple direct reports and lead project teams as needed. The position involves full-time research and the appointee has the freedom, and is expected, to patent/publish the results of their research and/or scholarship.

Preferred Qualifications:

The appointee is expected to be both highly independent and collaborative, and s/he will have significant leeway in the scope and design of projects. A key requirement is that the individual have the ability to see intellectually and technically complex projects through to their conclusion, which will involve developing methodological approaches and reviewing, analyzing, and interpreting scientific data and results from the project. Great autonomy and ability to exhibit independent decision making is expected in designing and implementing strategies for achieving company research and development goals.

The appointee will write papers for publication based on research, compose project reports and contribute to grant/contract applications as necessary; present at seminars and national meetings; network and meet with scientific leaders at other companies and universities; and participate in research group/project team meetings that may include oral and/or written brief reports. The appointee will be expected to supervise research personnel including staff, undergraduate and/or graduate students, providing training and guidance with regard to specific techniques and technology.

The appointee may assist students/interns in their research efforts, acting as a resource and a mentor. This requires excellent communication and teaching skills and thorough knowledge of the technical aspects of the various scientific procedures to be conducted.

Demonstrated experience and/or expertise in the following techniques:

  • Bioconjugation chemistry and/or analytical characterization of bioconjugates
  • Formulation of vaccine adjuvants and/or APIs
  • Analytical characterization of formulated APIs, including stability analysis
  • Expertise in analytical method development and troubleshooting
  • Experimental design with appropriate controls included
  • Proven ability to use experimental data to rationally develop the next experiment
  • Assessment of drug delivery systems and API formulations in vitro and in vivo

Preferred Skills and Experience:

  • Has theoretical, practical and technical scientific knowledge of an experienced PhD scientist with exceptional technical competencies.
  • Oversee day-to-day operations in laboratory including personnel and project management. Effectively manages at least 1 laboratory research and/or technical staff with strong leadership skills.
  • Designs and executes a wide range of experiments independently and proactively incorporates new technologies into practice with minimal or no supervision and conducts trouble shooting activities to mitigate risk and safety concerns.
  • Performs complex data management and analysis with minimum or no oversight.
  • Prepares detailed verbal or written summaries of results with interpretation for manager and/or project teams. Writes specific technical sections of internal and external reports with limited supervision.
  • Leads in some grant, contract and manuscript writing with limited input from supervisor.
  • Presents effectively to internal and external meetings and is responsible for sharing relevant scientific information from internal and external meetings with appropriate colleagues.
  • Established networking skills through interactions with scientists outside of primary project roles.
  • Initiates coordination of the efforts of technical and scientific staff to achieve project objectives, and milestones and contributes to relevant project teams
  • Trains incoming and/or junior scientists on instrumentation and methods. Demonstrated experience of excellent research capabilities required to carry out innovative and insightful research

About Inimmune

Inimmune was formed from an experienced, close-knit team of biotech/pharmaceutical industry professionals. This team of chemists, immunologists and formulation scientists have been at the cutting edge of innovation for over 10 years as former GSK Vaccines scientists and investigators. They now are working to create new immunotherapies directed at making meaningful and lasting clinical impacts in the areas of allergy, autoimmunity, infectious disease and cancer. Through its technology, assets, expertise and favorable IP positioning, Inimmune is poised to stand up and become a leader in the fields of immunotherapy, infectious disease and immuno-oncology. Inimmune is headquartered in beautiful Montana. It is located in Missoula, a culturally vibrant community of about 70,000, surrounded by mountain grandeur which was recently ranked in the “top 20 best college towns with a population of less than 250,000” by the American Institute for Economic Research and ranked 9th in Outside Magazine’s “The 16 Greatest Places to Live in America” in 2014. Many national publications recognize Missoula for its high quality of life. Abundant recreational opportunities in surrounding state and national forests and nearby Glacier National Park and Yellowstone National Park complement a thriving intellectual atmosphere.

To learn more about Inimmune, please visit our website at www.Inimmune.com

Position is open until filled

Please submit the following application materials:

  • Letter of Interest – addressing the stated required skills for the position and motivation to join Inimmune
  • Detailed resume listing education and describing work experience
  • Names and contact information for three (3) professional references

Our goal at Inimmune is to recruit, hire, and maintain a diverse workforce. Equal employment opportunity is good business. It is also the law. Equal opportunity applies to all aspects of employment, including recruitment, selection, hiring, training, transfer, promotion, termination, compensation, and benefits. As an equal opportunity employer, Inimmune does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. Furthermore, Inimmune will make reasonable accommodations for qualified individuals with known disabilities unless doing so would result in an undue hardship or a substantial safety health risk.

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics.

Contact

© Copyright 2022 Inimmune. All Rights Reserved.

Website Design by Digital Marketing Missoula
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.

TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING